CD63 and non-small cell lung carcinoma: To further confirm these findings, we evaluated the interaction between RBC‐derived exosomes and NSCLC cells by performing immunofluorescence staining using an anti‐CD63 antibody, a widely accepted marker for exosomes.[33] Following a 24 h incubation, CD63‐positive puncta were detected in NSCLC cells treated with exosomes from both lung cancer patients and healthy controls, indicating cellular association through binding and/or uptake (Figure3A,B).